Human toxin-based recombinant immunotoxins/chimeric proteins as a drug delivery system for targeted treatment of human diseases

Bibliography

• Mathew M, Verma RS. Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy. Cancer Sci 2009;100(8):1359-65
   PubMed Web of Science ®Google Scholar
• Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256(5517):495-7
   PubMed Web of Science ®Google Scholar
• Skerra A, Pluckthun A. Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science 1988;240(4855):1038-41
   PubMed Web of Science ®Google Scholar
• Toleikis L, Broders O, Dubel S. Cloning single-chain antibody fragments (scFv) from hybridoma cells. Methods Mol Med 2004;94:447-58
   PubMedGoogle Scholar
• Chaudhary VK, Queen C, Junghans RP, A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature 1989;339(6223):394-7
   PubMed Web of Science ®Google Scholar
• Pastan I, Hassan R, FitzGerald DJ, Immunotoxin treatment of cancer. Annu Rev Med 2007;58:221-37
   PubMed Web of Science ®Google Scholar
• Brinkmann U, Pai LH, FitzGerald DJ, B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc Natl Acad Sci USA 1991;88(19):8616-20
   PubMed Web of Science ®Google Scholar
• Benhar I, Pastan I. Identification of residues that stabilize the single-chain Fv of monoclonal antibodies B3. J Biol Chem 1995;270(40):23373-80
   PubMed Web of Science ®Google Scholar
• Zhu Z, Presta LG, Zapata G, Remodeling domain interfaces to enhance heterodimer formation. Protein Sci 1997;6(4):781-8
   PubMed Web of Science ®Google Scholar
• Pai-Scherf LH, Villa J, Pearson D, Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. Clin Cancer Res 1999;5(9):2311-15
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Wilson WH, Bergeron K, Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 2001;345(4):241-7
   PubMed Web of Science ®Google Scholar
• Multani PS, O'Day S, Nadler LM, Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma. Clin Cancer Res 1998;4(11):2599-604
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Wilson WH, White JD, Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000;18(8):1622-36
   PubMed Web of Science ®Google Scholar
• Schnell R, Borchmann P, Staak JO, Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma. Ann Oncol 2003;14(5):729-36
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Wilson WH, Robbins D, Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood 1999;94(10):3340-8
   PubMed Web of Science ®Google Scholar
• Amlot PL, Stone MJ, Cunningham D, A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 1993;82(9):2624-33
   PubMed Web of Science ®Google Scholar
• Sausville EA, Headlee D, Stetler-Stevenson M, Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study. Blood 1995;85(12):3457-65
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Squires DR, Stetler-Stevenson M, Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 2005;23(27):6719-29
   PubMed Web of Science ®Google Scholar
• Schnell R, Staak O, Borchmann P, A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. Clin Cancer Res 2002;8(6):1779-86
   PubMed Web of Science ®Google Scholar
• Francisco JA, Schreiber GJ, Comereski CR, In vivo efficacy and toxicity of a single-chain immunotoxin targeted to CD40. Blood 1997;89(12):4493-500
   PubMed Web of Science ®Google Scholar
• Peipp M, Kupers H, Saul D, A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells. Cancer Res 2002;62(10):2848-55
   PubMed Web of Science ®Google Scholar
• Pai LH, Wittes R, Setser A, Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nat Med 1996;2(3):350-3
   PubMed Web of Science ®Google Scholar
• Posey JA, Khazaeli MB, Bookman MA, A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors. Clin Cancer Res 2002;8(10):3092-9
   PubMed Web of Science ®Google Scholar
• Azemar M, Djahansouzi S, Jager E, Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2. Breast Cancer Res Treat 2003;82(3):155-64
   PubMed Web of Science ®Google Scholar
• Goldberg MR, Heimbrook DC, Russo P, Phase I clinical study of the recombinant oncotoxin TP40 in superficial bladder cancer. Clin Cancer Res 1995;1(1):57-61
   PubMed Web of Science ®Google Scholar
• Sampson JH, Akabani G, Archer GE, Progress report of a phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 2003;65(1):27-35
   PubMed Web of Science ®Google Scholar
• Hassan R, Bullock S, Premkumar A, Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 2007;13(17):5144-9
   PubMed Web of Science ®Google Scholar
• Foss FM, Bacha P, Osann KE, Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clin Lymphoma 2001;1(4):298-302
   PubMedGoogle Scholar
• Dang NH, Hagemeister FB, Pro B, Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol 2004;22(20):4095-102
   PubMed Web of Science ®Google Scholar
• Frankel AE, Fleming DR, Hall PD, A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. Clin Cancer Res 2003;9(10 Pt 1):3555-61
   PubMed Web of Science ®Google Scholar
• Vallera DA, Seo SY, Panoskaltsis-Mortari A, Targeting myeloid leukemia with a DT(390)-mIL-3 fusion immunotoxin: ex vivo and in vivo studies in mice. Protein Eng 1999;12(9):779-85
   PubMedGoogle Scholar
• Rand RW, Kreitman RJ, Patronas N, Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 2000;6(6):2157-65
   PubMed Web of Science ®Google Scholar
• Weber FW, Floeth F, Asher A, Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. Acta Neurochir Suppl 2003;88:93-103
   PubMedGoogle Scholar
• Puri RK, Leland P, Obiri NI, Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR). Blood 1996;87(10):4333-9
   PubMed Web of Science ®Google Scholar
• Kawakami K, Kawakami M, Joshi BH, Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer. Cancer Res 2001;61(16):6194-200
   PubMed Web of Science ®Google Scholar
• Frankel AE, Powell BL, Hall PD, Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin Cancer Res 2002;8(5):1004-13
   PubMed Web of Science ®Google Scholar
• Handa JT, Houston LL, Jaffe GJ. The antiproliferative effect of a transferrin-toxin on human retinal pigment epithelial cells and rabbit fibroblasts. Invest Ophthalmol Vis Sci 1993;34(12):3419-28
   PubMed Web of Science ®Google Scholar
• Nechushtan A, Yarkoni S, Marianovsky I, Adenocarcinoma cells are targeted by the new GnRH-PE66 chimeric toxin through specific gonadotropin-releasing hormone binding sites. J Biol Chem 1997;272(17):11597-603
   PubMed Web of Science ®Google Scholar
• Ben-Yehudah A, Lorberboum-Galski H. Targeted cancer therapy with gonadotropin-releasing hormone chimeric proteins. Expert Rev Anticancer Ther 2004;4(1):151-61
   PubMedGoogle Scholar
• Ben-Yehudah A, Prus D, Lorberboum-Galski H. I.V. Administration of L-GNRH-PE66 efficiently inhibits growth of colon adenocarcinoma xenografts in nude mice. Int J Cancer 2001;92(2):263-8
   PubMed Web of Science ®Google Scholar
• Ben-Yehudah A, Yarkoni S, Nechushtan A, Linker-based GnRH-PE chimeric proteins inhibit cancer growth in nude mice. Med Oncol 1999;16(1):38-45
   PubMed Web of Science ®Google Scholar
• Ben-Yehudah A, Aqeilan R, Belostotsky R, Utilizing chimeric proteins for exploring the cellular fate of endogenous proteins. Biochem Biophys Res Commun 2002;290(1):332-8
   PubMed Web of Science ®Google Scholar
• Piascik P. FDA approves fusion protein for treatment of lymphoma. J Am Pharm Assoc 1999;39(4):571-2
   Google Scholar
• Foss FM, Saleh MN, Krueger JG, Diphtheria toxin fusion proteins. Curr Top Microbiol Immunol 1998;234:63-81
   PubMed Web of Science ®Google Scholar
• Saleh MN, LeMaistre CF, Kuzel TM, Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. J Am Acad Dermatol 1998;39(1):63-73
   PubMed Web of Science ®Google Scholar
• Lichtenstein M, Ben-Yehudah A, Belostotsky R, Utilizing a GnRH-based chimeric protein for the detection of adenocarcinoma. Int J Oncol 2005;27(1):143-8
   PubMed Web of Science ®Google Scholar
• Eaveri R, Ben-Yehudah A, Lorberboum-Galski H. Surface antigens/receptors for targeted cancer treatment: the GnRH receptor/binding site for targeted adenocarcinoma therapy. Curr Cancer Drug Targets 2004;4(8):673-87
   PubMed Web of Science ®Google Scholar
• Fishman A, Lorberboum-Galski H. Targeted elimination of cells expressing the high-affinity receptor for IgE (Fc epsilon RI) by a Pseudomonas exotoxin-based chimeric protein. Eur J Immunol 1997;27(2):486-94
   PubMed Web of Science ®Google Scholar
• Fishman A, Prus D, Belostotsky R, Targeted Fc2′-3-PE40 chimeric protein abolishes passive cutaneous anaphylaxis in mice. Clin Exp Immunol 2000;119(3):398-403
   PubMed Web of Science ®Google Scholar
• Brenner T, Steinberger I, Soffer D, A novel antigen-toxin chimeric protein: myelin basic protein-pseudomonas exotoxin (MBP-PE 40) for treatment of experimental autoimmune encephalomyelitis. Immunol Lett 1999;68(2-3):403-10
   PubMed Web of Science ®Google Scholar
• Bolognesi A, Polito L, Tazzari PL, In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins. Br J Haematol 2000;110(2):351-61
   PubMed Web of Science ®Google Scholar
• Endo Y, Mitsui K, Motizuki M, The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. The site and the characteristics of the modification in 28 S ribosomal RNA caused by the toxins. J Biol Chem 1987;262(12):5908-12
   PubMed Web of Science ®Google Scholar
• Zamboni M, Brigotti M, Rambelli F, High-pressure-liquid-chromatographic and fluorimetric methods for the determination of adenine released from ribosomes by ricin and gelonin. Biochem J 1989;259(3):639-43
   PubMed Web of Science ®Google Scholar
• Mohanraj D, Ramakrishnan S. Cytotoxic effects of ricin without an interchain disulfide bond: genetic modification and chemical crosslinking studies. Biochim Biophys Acta 1995;1243(3):399-406
   PubMed Web of Science ®Google Scholar
• Ramakrishnan S, Bjorn MJ, Houston LL. Recombinant ricin A chain conjugated to monoclonal antibodies: improved tumor cell inhibition in the presence of lysosomotropic compounds. Cancer Res 1989;49(3):613-17
   PubMed Web of Science ®Google Scholar
• Cook JP, Savage PM, Lord JM, Biologically active interleukin 2-ricin A chain fusion proteins may require intracellular proteolytic cleavage to exhibit a cytotoxic effect. Bioconjug Chem 1993;4(6):440-7
   PubMed Web of Science ®Google Scholar
• Dore JM, Gras E, Wijdenes J. Expression and activity of a recombinant chimeric protein composed of pokeweed antiviral protein and of human interleukin-2. FEBS Lett 1997;402(1):50-2
   PubMed Web of Science ®Google Scholar
• Francisco JA, Gawlak SL, Siegall CB. Construction, expression, and characterization of BD1-G28-5 sFv, a single-chain anti-CD40 immunotoxin containing the ribosome-inactivating protein bryodin 1. J Biol Chem 1997;272(39):24165-9
   PubMed Web of Science ®Google Scholar
• Cao Y, Marks JD, Marks JW, Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies. Cancer Res 2009;69(23):8987-95
   PubMed Web of Science ®Google Scholar
• Cizeau J, Grenkow DM, Brown JG, Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of the plant toxin bouganin. J Immunother 2009;32(6):574-84
   PubMed Web of Science ®Google Scholar
• Kreitman RJ. Getting plant toxins to fuse. Leuk Res 1997;21(10):997-9
   PubMed Web of Science ®Google Scholar
• Carroll SF, Collier RJ. Active site of Pseudomonas aeruginosa exotoxin A. Glutamic acid 553 is photolabeled by NAD and shows functional homology with glutamic acid 148 of diphtheria toxin. J Biol Chem 1987;262(18):8707-11
   PubMed Web of Science ®Google Scholar
• Uchida T, Pappenheimer AM Jr, Harper AA. Reconstitution of diphtheria toxin from two nontoxic cross-reacting mutant proteins. Science 1972;175(24):901-3
   PubMedGoogle Scholar
• Uchida T, Pappenheimer AM Jr, Greany R. Diphtheria toxin and related proteins. I. Isolation and properties of mutant proteins serologically related to diphtheria toxin. J Biol Chem 1973;248(11):3838-44
   PubMed Web of Science ®Google Scholar
• Iglewski BH, Liu PV, Kabat D. Mechanism of action of Pseudomonas aeruginosa exotoxin Aiadenosine diphosphate-ribosylation of mammalian elongation factor 2 in vitro and in vivo. Infect Immun 1977;15(1):138-44
   PubMed Web of Science ®Google Scholar
• Van Ness BG, Howard JB, Bodley JW. ADP-ribosylation of elongation factor 2 by diphtheria toxin. Isolation and properties of the novel ribosyl-amino acid and its hydrolysis products. J Biol Chem 1980;255(22):10717-20
   PubMedGoogle Scholar
• Phan LD, Perentesis JP, Bodley JW. Saccharomyces cerevisiae elongation factor 2. Mutagenesis of the histidine precursor of diphthamide yields a functional protein that is resistant to diphtheria toxin. J Biol Chem 1993;268(12):8665-8
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Batra JK, Seetharam S, Single-chain immunotoxin fusions between anti-Tac and Pseudomonas exotoxin: relative importance of the two toxin disulfide bonds. Bioconjug Chem 1993;4(2):112-20
   PubMed Web of Science ®Google Scholar
• Williams DP, Snider CE, Strom TB, Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J Biol Chem 1990;265(20):11885-9
   PubMed Web of Science ®Google Scholar
• Chaudhary VK, FitzGerald DJ, Pastan I. A proper amino terminus of diphtheria toxin is important for cytotoxicity. Biochem Biophys Res Commun 1991;180(2):545-51
   PubMed Web of Science ®Google Scholar
• Kreitman RJ. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. BioDrugs 2009;23(1):1-13
   PubMed Web of Science ®Google Scholar
• Frankel AE. Reducing the immune response to immunotoxin. Clin Cancer Res 2004;10(1 Pt 1):13-15
   PubMed Web of Science ®Google Scholar
• Wang H, Song S, Kou G, Treatment of hepatocellular carcinoma in a mouse xenograft model with an immunotoxin which is engineered to eliminate vascular leak syndrome. Cancer Immunol Immunother 2007;56(11):1775-83
   PubMed Web of Science ®Google Scholar
• Hall PD, Virella G, Willoughby T, Antibody response to DT-GM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte-macrophage colony stimulating factor (GM), during a phase I trial of patients with relapsed or refractory acute myeloid leukemia. Clin Immunol 2001;100(2):191-7
   PubMed Web of Science ®Google Scholar
• Hertler AA, Spitler LE, Frankel AE. Humoral immune response to a ricin A chain immunotoxin in patients with metastatic melanoma. Cancer Drug Deliv 1987;4(4):245-53
   PubMedGoogle Scholar
• Tsutsumi Y, Onda M, Nagata S, Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc Natl Acad Sci USA 2000;97(15):8548-53
   PubMed Web of Science ®Google Scholar
• Hansen JK, Weldon JE, Xiang L, A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in mice. J Immunother 2010;33(3):297-304
   PubMed Web of Science ®Google Scholar
• Chen SY, Zani C, Khouri Y, Design of a genetic immunotoxin to eliminate toxin immunogenicity. Gene Ther 1995;2(2):116-23
   PubMed Web of Science ®Google Scholar
• Jin Z, El-Deiry WS. Overview of cell death signaling pathways. Cancer Biol Ther 2005;4(2):139-63
   PubMed Web of Science ®Google Scholar
• Chipuk JE, Moldoveanu T, Llambi F, The BCL-2 family reunion. Mol Cell 2010;37(3):299-310
   PubMed Web of Science ®Google Scholar
• Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008;9(1):47-59
   PubMed Web of Science ®Google Scholar
• Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 2010;11(9):621-32
   PubMed Web of Science ®Google Scholar
• Ow YP, Green DR, Hao Z, Cytochrome c: functions beyond respiration. Nat Rev Mol Cell Biol 2008;9(7):532-42
   PubMed Web of Science ®Google Scholar
• Strasser A. The role of BH3-only proteins in the immune system. Nat Rev Immunol 2005;5(3):189-200
   PubMed Web of Science ®Google Scholar
• Aqeilan R, Kedar R, Ben-Yehudah A, Mechanism of action of interleukin-2 (IL-2)-Bax, an apoptosis-inducing chimaeric protein targeted against cells expressing the IL-2 receptor. Biochem J 2003;370(Pt 1):129-40
   PubMedGoogle Scholar
• Lorberboum-Galski H, Barrett LV, Kirkman RL, Cardiac allograft survival in mice treated with IL-2-PE40. Proc Natl Acad Sci USA 1989;86(3):1008-12
   PubMed Web of Science ®Google Scholar
• Lorberboum-Galski H, FitzGerald D, Chaudhary V, Cytotoxic activity of an interleukin 2-Pseudomonas exotoxin chimeric protein produced in Escherichia coli. Proc Natl Acad Sci USA 1988;85(6):1922-6
   PubMed Web of Science ®Google Scholar
• Lorberboum-Galski H, Garsia RJ, Gately M, IL2-PE664Glu, a new chimeric protein cytotoxic to human-activated T lymphocytes. J Biol Chem 1990;265(27):16311-17
   PubMed Web of Science ®Google Scholar
• Lorberboum-Galski H, Kozak RW, Waldmann TA, Interleukin 2 (IL2) PE40 is cytotoxic to cells displaying either the p55 or p70 subunit of the IL2 receptor. J Biol Chem 1988;263(35):18650-6
   PubMed Web of Science ®Google Scholar
• Lorberboum-Galski H, Lafyatis R, Case JP, Administration of IL-2-PE40 via osmotic pumps prevents adjuvant induced arthritis in rats. Improved therapeutic index of IL-2-PE40 administered by continuous infusion. Int J Immunopharmacol 1991;13(2-3):305-15
   PubMed Web of Science ®Google Scholar
• Kozak RW, Lorberboum-Galski H, Jones L, IL-2-PE40 prevents the development of tumors in mice injected with IL-2 receptor expressing EL4 transfectant tumor cells. J Immunol 1990;145(8):2766-71
   PubMed Web of Science ®Google Scholar
• Beraud E, Lorberboum-Galski H, Chan CC, Immunospecific suppression of encephalitogenic-activated T lymphocytes by chimeric cytotoxin IL-2-PE40. Cell Immunol 1991;133(2):379-89
   PubMed Web of Science ®Google Scholar
• BenEzra D, Maftzir G, Hochberg E, Ocular distribution of the chimeric protein IL2-PE40. Curr Eye Res 1995;14(2):153-8
   PubMed Web of Science ®Google Scholar
• Herbort CP, de Smet MD, Roberge FG, Treatment of corneal allograft rejection with the cytotoxin IL-2-PE40. Transplantation 1991;52(3):470-4
   PubMed Web of Science ®Google Scholar
• Ogata M, Lorberboum-Galski H, FitzGerald D, IL-2-PE40 is cytotoxic for activated T lymphocytes expressing IL-2 receptors. J Immunol 1988;141(12):4224-8
   PubMed Web of Science ®Google Scholar
• Roberge FG, Lorberboum-Galski H, Le Hoang P, Selective immunosuppression of activated T cells with the chimeric toxin IL-2-PE40. Inhibition of experimental autoimmune uveoretinitis. J Immunol 1989;143(11):3498-502
   PubMed Web of Science ®Google Scholar
• Steinberger I, Ben-Bassat H, Hochberg E, Interleukin-2 (IL-2) receptor alpha, beta and gamma subunit expression as a function of B-cell lineage ontogeny: the use of IL-2-PE66(4Glu) to characterize internalization via IL-2 receptor subunits. Scand J Immunol 1997;46(2):129-36
   PubMed Web of Science ®Google Scholar
• Steinberger I, Brenner T, Lorberboum-Galski H. Interleukin-2 Pseudomonas exotoxin chimeric protein is cytotoxic to B cell cultures derived from myasthenia gravis patients. J Neurol Sci 1995;133(1-2):183-91
   PubMed Web of Science ®Google Scholar
• Steinberger I, Brenner T, Lorberboum-Galski H. Interleukin 2 pseudomonas exotoxin (IL2-PE66(4)Glu) chimeric protein kills B cells from patients with Myasthenia gravis. Cell Immunol 1996;169(1):55-61
   PubMed Web of Science ®Google Scholar
• Aqeilan R, Yarkoni S, Lorberboum-Galski H. Interleukin 2-Bax: a novel prototype of human chimeric proteins for targeted therapy. FEBS Lett 1999;457(2):271-6
   PubMed Web of Science ®Google Scholar
• Azar Y, Lorberboum-Galski H. GnRH-Bik/Bax/Bak chimeric proteins target and kill adenocarcinoma cells; the general use of pro-apoptotic proteins of the Bcl-2 family as novel killing components of targeting chimeric proteins. Apoptosis 2000;5(6):531-42
   PubMed Web of Science ®Google Scholar
• Belostotsky R, Lorberboum-Galski H. Apoptosis-inducing human-origin Fcepsilon-Bak chimeric proteins for targeted elimination of mast cells and basophils: a new approach for allergy treatment. J Immunol 2001;167(8):4719-28
   PubMed Web of Science ®Google Scholar
• Luo X, Budihardjo I, Zou H, Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998;94(4):481-90
   PubMed Web of Science ®Google Scholar
• Wang K, Yin XM, Chao DT, BID: a novel BH3 domain-only death agonist. Genes Dev 1996;10(22):2859-69
   PubMed Web of Science ®Google Scholar
• Li H, Zhu H, Xu CJ, Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998;94(4):491-501
   PubMed Web of Science ®Google Scholar
• Yin XM. Signal transduction mediated by Bid, a pro-death Bcl-2 family proteins, connects the death receptor and mitochondria apoptosis pathways. Cell Res 2000;10(3):161-7
   PubMed Web of Science ®Google Scholar
• Shan LQ, Qiu XC, Xu YM, scFv-mediated delivery of truncated BID suppresses HER2-positive osteosarcoma growth and metastasis. Cancer Biol Ther 2008;7(11):1717-22
   PubMed Web of Science ®Google Scholar
• Wang F, Ren J, Qiu XC, Selective cytotoxicity to HER2-positive tumor cells by a recombinant e23sFv-TD-tBID protein containing a furin cleavage sequence. Clin Cancer Res 2010;16(8):2284-94
   PubMed Web of Science ®Google Scholar
• Li J, Yuan J. Caspases in apoptosis and beyond. Oncogene 2008;27(48):6194-206
   PubMed Web of Science ®Google Scholar
• Jia LT, Zhang LH, Yu CJ, Specific tumoricidal activity of a secreted proapoptotic protein consisting of HER2 antibody and constitutively active caspase-3. Cancer Res 2003;63(12):3257-62
   PubMed Web of Science ®Google Scholar
• Zhang DX, Zhao PT, Xia L, Potent inhibition of human gastric cancer by HER2-directed induction of apoptosis with anti-HER2 antibody and caspase-3 fusion protein. Gut 2010;59(3):292-9
   PubMed Web of Science ®Google Scholar
• Wang LF, Zhou Y, Xu YM, A caspase-6 and anti-HER2 antibody chimeric tumor-targeted proapoptotic molecule decreased metastasis of human osteosarcoma. Cancer Invest 2009 27(7):774-80
   PubMed Web of Science ®Google Scholar
• Shteingart S, Rapoport M, Grodzovski I, Therapeutic potency of IL2-caspase 3 targeted treatment in a murine experimental model of inflammatory bowel disease. Gut 2009;58(6):790-8
   PubMed Web of Science ®Google Scholar
• Sagiv Y, Kaminitz A, Lorberboum-Galski H, A fusion protein composed of IL-2 and caspase-3 ameliorates the outcome of experimental inflammatory colitis. Ann NY Acad Sci 2009 1173:791-7
   PubMed Web of Science ®Google Scholar
• Irony-Tur-Sinai M, Lichtenstein M, Brenner T, IL2-caspase3 chimeric protein controls lymphocyte reactivity by targeted apoptosis, leading to amelioration of experimental autoimmune encephalomyelitis. Int Immunopharmacol 2009;9(10):1236-43
   PubMed Web of Science ®Google Scholar
• Kurschus FC, Jenne DE. Delivery and therapeutic potential of human granzyme B. Immunol Rev 2010 235(1):159-71
   PubMedGoogle Scholar
• Rosenblum MG, Barth S. Development of novel, highly cytotoxic fusion constructs containing granzyme B: unique mechanisms and functions. Curr Pharm Des 2009;15(23):2676-92
   PubMed Web of Science ®Google Scholar
• Kurschus FC, Fellows E, Stegmann E, Granzyme B delivery via perforin is restricted by size, but not by heparan sulfate-dependent endocytosis. Proc Natl Acad Sci USA 2008 105(37):13799-804
   PubMed Web of Science ®Google Scholar
• Froelich CJ, Orth K, Turbov J, New paradigm for lymphocyte granule-mediated cytotoxicity. Target cells bind and internalize granzyme B, but an endosomolytic agent is necessary for cytosolic delivery and subsequent apoptosis. J Biol Chem 1996 271(46):29073-9
   PubMed Web of Science ®Google Scholar
• Bird CH, Sun J, Ung K, Cationic sites on granzyme B contribute to cytotoxicity by promoting its uptake into target cells. Mol Cell Biol 2005 25(17):7854-67
   PubMed Web of Science ®Google Scholar
• Shi L, Keefe D, Durand E, Granzyme B binds to target cells mostly by charge and must be added at the same time as perforin to trigger apoptosis. J Immunol 2005 174(9):5456-61
   PubMed Web of Science ®Google Scholar
• Bots M, Medema JP. Granzymes at a glance. J Cell Sci 2006 119(Pt 24):5011-4
   PubMed Web of Science ®Google Scholar
• Lieberman J. The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal. Nat Rev Immunol 2003 3(5):361-70
   PubMed Web of Science ®Google Scholar
• Grodzovski I, Lichtenstein M, Galski H, IL-2-granzyme A chimeric protein overcomes multidrug resistance (MDR) through a caspase 3-independent apoptotic pathway. Int J Cancer 2011;128(8):1966-80
   Google Scholar
• Enari M, Sakahira H, Yokoyama H, A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998 391(6662):43-50
   PubMed Web of Science ®Google Scholar
• Halenbeck R, MacDonald H, Roulston A, CPAN, a human nuclease regulated by the caspase-sensitive inhibitor DFF45. Curr Biol 1998 8(9):537-40
   PubMed Web of Science ®Google Scholar
• Mukae N, Enari M, Sakahira H, Molecular cloning and characterization of human caspase-activated DNase. Proc Natl Acad Sci USA 1998 95(16):9123-8
   PubMed Web of Science ®Google Scholar
• Nagata S. Apoptotic DNA fragmentation. Exp Cell Res 2000 256(1):12-8
   PubMed Web of Science ®Google Scholar
• Ben-Yehudah A, Aqeilan R, Robashkevich D, Using apoptosis for targeted cancer therapy by a new gonadotropin releasing hormone-DNA fragmentation factor 40 chimeric protein. Clin Cancer Res 2003 9(3):1179-90
   PubMed Web of Science ®Google Scholar
• Mahmud H, Dalken B, Wels WS. Induction of programmed cell death in ErbB2/HER2-expressing cancer cells by targeted delivery of apoptosis-inducing factor. Mol Cancer Ther 2009 8(6):1526-35
   PubMed Web of Science ®Google Scholar
• Cleveland JL, Ihle JN. Contenders in FasL/TNF death signaling. Cell 1995 81(4):479-82
   PubMed Web of Science ®Google Scholar
• Pitti RM, Marsters SA, Ruppert S, Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996 271(22):12687-90
   PubMed Web of Science ®Google Scholar
• LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003 10(1):66-75
   PubMed Web of Science ®Google Scholar
• Kischkel FC, Lawrence DA, Chuntharapai A, Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000 12(6):611-20
   PubMed Web of Science ®Google Scholar
• Sprick MR, Weigand MA, Rieser E, FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000 12(6):599-609
   PubMed Web of Science ®Google Scholar
• Pan G, Ni J, Wei YF, An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997 277(5327):815-18
   PubMed Web of Science ®Google Scholar
• Carlo-Stella C, Lavazza C, Locatelli A, Targeting TRAIL agonistic receptors for cancer therapy. Clin Cancer Res 2007 13(8):2313-17
   PubMed Web of Science ®Google Scholar
• Bremer E, Kuijlen J, Samplonius D, Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2. Int J Cancer 2004 109(2):281-90
   PubMed Web of Science ®Google Scholar
• Bremer E, Samplonius DF, Peipp M, Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7. Cancer Res 2005 65(8):3380-8
   PubMed Web of Science ®Google Scholar
• Ogasawara J, Watanabe-Fukunaga R, Adachi M, Lethal effect of the anti-Fas antibody in mice. Nature 1993 364(6440):806-9
   PubMed Web of Science ®Google Scholar
• Rensing-Ehl A, Frei K, Flury R, Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur J Immunol 1995 25(8):2253-8
   PubMed Web of Science ®Google Scholar
• Schneider P, Holler N, Bodmer JL, Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998;187(8):1205-13
   PubMed Web of Science ®Google Scholar
• Bremer E, ten Cate B, Samplonius DF, CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia. Blood 2006 107(7):2863-70
   PubMed Web of Science ®Google Scholar
• Zewe M, Rybak SM, Dubel S, Cloning and cytotoxicity of a human pancreatic RNase immunofusion. Immunotechnology 1997 3(2):127-36
   PubMedGoogle Scholar
• Psarras K, Ueda M, Yamamura T, Human pancreatic RNase1-human epidermal growth factor fusion: an entirely human ‘immunotoxin analog’ with cytotoxic properties against squamous cell carcinomas. Protein Eng 1998 11(12):1285-92
   PubMedGoogle Scholar
• Futami J, Seno M, Ueda M, Inhibition of cell growth by a fused protein of human ribonuclease 1 and human basic fibroblast growth factor. Protein Eng 1999 12(11):1013-19
   PubMedGoogle Scholar
• Psarras K, Ueda M, Tanabe M, Targeting activated lymphocytes with an entirely human immunotoxin analogue: human pancreatic RNase1-human IL-2 fusion. Cytokine 2000 12(6):786-90
   PubMed Web of Science ®Google Scholar
• De Lorenzo C, Nigro A, Piccoli R, A new RNase-based immunoconjugate selectively cytotoxic for ErbB2-overexpressing cells. FEBS Lett 2002 516(1-3):208-12
   PubMed Web of Science ®Google Scholar
• Newton DL, Nicholls PJ, Rybak SM, Expression and characterization of recombinant human eosinophil-derived neurotoxin and eosinophil-derived neurotoxin-anti-transferrin receptor sFv. J Biol Chem 1994 269(43):26739-45
   PubMed Web of Science ®Google Scholar
• Yoon JM, Han SH, Kown OB, Cloning and cytotoxicity of fusion proteins of EGF and angiogenin. Life Sci 1999;64(16):1435-45
   PubMed Web of Science ®Google Scholar
• Newton DL, Pollock D, DiTullio P, Antitransferrin receptor antibody-RNase fusion protein expressed in the mammary gland of transgenic mice. J Immunol Methods 1999 231(1-2):159-67
   PubMed Web of Science ®Google Scholar
• Huhn M, Sasse S, Tur MK, Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma. Cancer Res 2001 61(24):8737-42
   PubMed Web of Science ®Google Scholar
• Tur MK, Neef I, Jager G, Immunokinases, a novel class of immunotherapeutics for targeted cancer therapy. Curr Pharm Des 2009;15(23):2693-9
   PubMed Web of Science ®Google Scholar
• Tur MK, Neef I, Jost E, Targeted restoration of down-regulated DAPK2 tumor suppressor activity induces apoptosis in Hodgkin lymphoma cells. J Immunother 2009 32(5):431-41
   PubMed Web of Science ®Google Scholar